Forest Labs Targeted By Actavis, Say Unconfirmed Media Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
Actavis is reported to be in talks to acquire the U.S. specialty firm Forest Labs in a move that would boost Actavis’s branded products business.
You may also be interested in...
Watson Becomes Actavis: Name Change To Reflect Greater International Focus
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.